Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) =< 3 x upper limit of normal (ULN); if liver metastases, =< 5 x upper limit of normal (ULN)
Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) =< 2.5 upper limits of normal (ULN)\r\n* Unless due to hepatic metastases in which case levels =< 5 x ULN are allowed
Obtained within 14 days prior to treatment start: Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 2.5 x upper limit of normal (ULN); if the patient has liver metastases, ALT and AST must still be =< 2.5 x ULN; patients with liver metastases and AST/ALT above this limit will not be enrolled
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) < 3 × upper limit of normal (ULN); if liver metastases, then < 5 × ULN
Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 2.5 x upper limit of normal (ULN) or =< 5 x ULN if liver metastases are present
Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) < 2.5 x upper limit of normal if no documented liver disease or < 5 x upper limit of normal if documented liver disease
Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) =< upper limit of normal (ULN) in the absence of malignancy within the liver within 14 days of starting cycle 1 day 1 treatment
In the absence of liver metastases, alanine aminotransferase (ALT) and aspartate aminotransferase (AST) < 2.5 x upper limit of normal (ULN); if the patient has liver metastases, ALT and AST < 5 x ULN
Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 3 x the ULN; for patients with documented liver metastases, AST/ALT =< 5.0 times the upper limit of normal, within 14 days before the first dose of cabozantinib
In the absence of liver metastases, alanine aminotransferase (ALT) and aspartate aminotransferase (AST) < 2.5 x upper limit of normal (ULN); if the patient has liver metastases, ALT and AST < 5 x ULN
In the absence of liver metastases, alanine aminotransferase (ALT) and aspartate aminotransferase (AST) < 2.5 x upper limit of normal (ULN); if a patient has liver metastases, ALT and AST < 5 x ULN
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ?3.0 × the upper limit of normal(ULN), even in the presence of liver metastases.
Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) < 2.5 times upper limit of normal (ULN) if no demonstrable liver metastases or < 5 times ULN in the presence of liver metastases obtained =< 14 days prior to study initiation
Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) =< 3 X upper limit of normal (ULN) or < 5 X ULN in the presence of liver metastases
Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) >2.5 times the upper limit of normal (ULN) if no demonstrable liver metastases or >5 times ULN in the presence of liver metastases
Aspartate aminotransferase/alanine aminotransferase (AST/ALT) =< 1.5 x institutional upper limit of normal (ULN) or if liver metastasis, =< 2.5 x ULN
Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) ? 2.5 × upper limit of normal (ULN). In the case of known (i.e., radiological or biopsy documented) liver metastasis, serum transaminase levels must be < 5 x ULN.
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2.5 x upper limit normal (ULN), < 5 x in patients with known liver metastases
Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 2.5 x upper limit of normal (ULN) or =< 5 X ULN for patients with liver metastases
Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) =< 3.0 x upper limit of normal (ULN) (=< 5.0 x ULN if liver metastases are involved)
(For both cohorts A and B): Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 2.5 x upper limit of normal (ULN) (=< 5 x ULN in patients with liver metastases)
Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) < 2.5 x upper limit of normal (ULN) (or < 5 x ULN if liver metastasis are present)
Alanine aminotransferase (ALT)/aspartate aminotransferase (AST) =< 2.5 x upper limit of normal (ULN) or =< 5 x ULN if documented liver metastases.
In the absence of liver metastases, alanine aminotransferase (ALT) and aspartate aminotransferase (AST) should be below 2.5 x the upper limit of normal (ULN); if the patient has liver metastases, ALT and AST should be < 5 x ULN
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2.5 x upper limit normal (ULN) or =< 5.0 x ULN if liver tumor is present, within 14 days start of study start
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2.5 x institutional upper limit of normal (ULN); for subjects with liver metastases, AST or ALT =< 5 x ULN
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2.5 x upper limit of normal (ULN) without, and =< 5 x ULN with hepatic metastasis
Aspartate and alanine aminotransferases (AST, ALT) =< 2.5 x upper limit of normal (ULN) (=< 5 x ULN, if documented liver metastases are present)
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2.5 x upper limit of normal (ULN) or 5.0 x upper limit of normal (ULN) in the setting of liver metastases
Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) =< 3 x upper limit normal (ULN), or =< 5 x ULN if documented liver metastases are present
Aspartate aminotransferase (AST) and/or alanine aminotransferase (ALT) ? 3 x upper limit of normal (ULN) (? 5.0 x ULN if liver metastases present)
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2.5 x upper limit of normal (ULN); for subjects with liver metastasis, ALT and AST =< 5 x ULN
Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) =< 2.5 × upper limit of normal (ULN); patient with liver metastases =< 5 × ULN
In the absence of liver metastases, alanine aminotransferase (AST) and aspartate aminotransferase (ALT) < 2.5 x upper limit of normal (ULN); if the patient has liver metastases, ALT and AST < 5 x ULN
ARM A COHORT 1: Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2 x upper limit of normal (ULN); if liver metastases are present then must be < 5 X the ULN
Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 2.5 x upper limit of normal (ULN) (=< 5 x ULN in patients with liver metastases)
Serum aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2.5 x upper limit of normal (ULN); if liver function abnormalities are due to hepatic metastasis, then AST and ALT =< 5 x ULN
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 3 x institutional upper limit of normal (ULN) or =< 5 x ULN for subjects with liver metastases
Aspartate and alanine aminotransferases (AST, ALT) =< 2.5 x upper limit of normal (ULN) (=< 5 x ULN, if documented liver metastases are present)
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT)? 2.5 × upper limit of normal (ULN) (if liver metastases are present, then?5 x ULN is allowed)
Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) within normal range (or =< 3.0 x upper limit of normal [ULN] if liver metastases are present)
Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 3 x upper limit of normal (ULN) or =< 5 x ULN if known hepatic metastases
Alanine aminotransferase (ALT)/aspartate aminotransferase (AST) =< 2.5 x upper limit of normal (ULN) or =< 5 x ULN if documented liver metastases
Alanine aminotransferase (ALT)/aspartate aminotransferase (AST) =< 2.5 x upper limit of normal (ULN) or =< 5 x ULN if documented liver metastases.
Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 2.5 x ULN or =< 5 x upper limits of normal (ULN) if liver metastases are present =< 14 days prior to registration
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) </= 2.5 x upper limit of normal\r\n(ULN); for subjects with liver metastasis, ALT and AST </= 5 x ULN within 3 weeks prior to initial treatment
Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) > 3 × the upper limit of normal (ULN) if no hepatic metastases are present; >5 × ULN if hepatic metastases are present.
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 3.0 x upper limit of normal (ULN); however, in the presence of liver metastases or in patients with refractory leukemias, AST and ALT must be < 5 x ULN
Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) =< 3 x upper limit of normal (ULN) (=< 5 x ULN in case of liver metastases)
Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) =< upper limit of normal (or < 3.0 x ULN if liver metastases are present)
In the absence of liver metastases, alanine aminotransferase (ALT) and aspartate aminotransferase (AST) < 2.5 x upper limit of normal (ULN)
Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 2.5 upper limit of normal (ULN) or =< 5 x ULN if liver metastases are present
Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) =< 2.5 x upper limit of normal (ULN) for patients with liver metastases and =< 2.0 x ULN for patients without liver metastases
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2.5 x upper limit of normal (ULN) without, and =< 5 x ULN with hepatic metastasis
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 3.0 x institutional upper limit of normal, unless due to liver metastases (=< 5 x ULN)
Aspartate aminotransferase (AST), alanine aminotransferase (ALT) =< 2.5 x upper limit of normal (ULN); patients with hepatic metastases: ALT and AST =< 5 x ULN
Aspartate Aminotransferase (AST) and Alanine Aminotransferase (ALT) ? 2.5 x Upper Limit of Normal (ULN) or ? 3.0 x ULN if liver tumor is present,
Serum aspartate aminotransferase (AST) and alanine transaminase (ALT) ? 2.5 upper limit of the normal range (ULN) (or ? 5 if hepatic metastases are present)
allow alanine aminotransferase (ALT) or aspartate aminotransferase (AST) up to 5x upper limit of normal (ULN) if liver metastases.
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2.5 x institutional upper limit of normal (ULN) or =< 5 x ULN if liver involved by lymphoma
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2.5 x upper limit of normal (ULN); if liver metastases are present, =< 5 x ULN
Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) =< 1.5 x upper limit of normal (ULN) and bilirubin =< ULN for patients without liver metastases
Hepatic: Total bilirubin ? 1.5 x the upper limit of normal (ULN). Alanine aminotransferase (ALT), aspartate aminotransferase (AST) ? 3.0 x ULN OR ? 5.0 x ULN for patients with liver metastases.
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) < 2.5 x upper limit of normal (ULN) unless liver metastases documented; in this latter case, AST and ALT < 5 x ULN required
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ? 5 × upper limit of normal (ULN) for cases involving liver metastasis and ? 2.5 ×ULN for all other cases
Within 14 days of study start: Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2.5 x upper limit normal (ULN) or =< 5.0 x ULN if liver tumor is present
If liver metastases present, aspartate aminotransferase (AST) and alanine aminotransferase (ALT) must be < 3 x upper limit of normal (ULN)
Aspartate and alanine aminotransferases (AST, ALT) =< 2.5 x upper limit of normal (ULN) (=< 5 x ULN, if documented liver metastases are present)
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2.5 x upper limit of normal (ULN) (Exception: =< 5 x ULN, if elevation is considered related to ASM/MCL)
Aspartate and alanine aminotransferases (AST, ALT) =< 2.5 x upper limit of normal (ULN) (=< 5 x ULN, if documented liver metastases are present)
In the absence of liver metastases, alanine aminotransferase (ALT) and aspartate aminotransferase (AST) < 2.5 x upper limit of normal (ULN). If the patient has liver metastases, ALT and AST < 5 x ULN.
Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) =< 2.5 x upper limit of normal (ULN) in the case of liver metastases or AST/ALT =< 1.5 x ULN in patients without liver metastases
Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ?2.0 x the institutional upper limit of normal (ULN), or, in patients with known liver metastases, ?5.0 x the institutional ULN.
Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) within normal range (or =< 3.0 x upper limit of normal [ULN] if liver metastases are present)
Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) =< 2.5 x upper limit of normal unless the liver is involved with tumor, in that case, ALT/AST must be =< 5 x ULN
Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 2.5 x upper limit of normal (ULN), or =< 5.0 x ULN if liver metastases are present
Alanine aminotransferase (ALT)/aspartate aminotransferase (AST) ?2.5 x upper limit of normal (ULN; ?5 x ULN is acceptable if liver metastases are present)
Serum aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2.5 x upper limit of normal (ULN); if liver function abnormalities are due to hepatic metastasis, then AST and ALT may be =< 5 x ULN
Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) >2.5 x upper limit of normal (ULN) if no demonstrable liver metastases or >5 x ULN in the presence of liver metastases
Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) < 3 x upper limit of normal (ULN) (< 5 x ULN if subject has liver metastases [mets])
Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) =< 3.0 x upper limit of normal (ULN) (=< 5.0 x ULN if liver metastases are involved)
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2.5 x institutional upper limit of normal (ULN)\r\n* NOTE: this applies to patient in the normal and renal dysfunction cohorts (N, R3 and R4); patients with elevated AST and/or ALT may be assigned to liver dysfunction cohorts
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2.5 x upper limit of normal (ULN) unless presence of hepatic metastasis in which case AST and ALT =< 5 x ULN are acceptable
Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) within 1.5 x normal range (or =< 3.0 x upper limit of normal [ULN] if liver metastases are present)
Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) =< 5 x upper limit of normal if liver metastases present; otherwise, then =< 2.5 x upper limit
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2.5 x upper limit of normal (ULN); in patients with liver dysfunction due to hepatic metastases, AST and ALT are permitted to be =< 5 times the ULN
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2.5 x upper limit of normal (ULN), unless there are liver metastases in which case AST and ALT =< 5.0 x ULN
Serum aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ? 2.5 Upper Limit of the Normal range (ULN) (or ? 5 if hepatic metastases are present)
Aspartate transaminase (AST) and alanine aminotransferase (ALT) ? 2.5 x upper limit of normal (ULN); or ? 5.0 × ULN if liver metastases are present.
AST (Aspartate aminotransferase (GOT) and ALT (Alanine aminotransferase (GPT)) < 3.0 × ULN (upper limit of normal) or ? 5 × ULN if subject has documented liver metastases
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2.5 x upper limit of normal (ULN); ALT and AST up to 5 x ULN if liver metastases present
Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) of =< 2.5 x the upper limit of normal (ULN) or =< 5 x ULN if hepatic disease involvement is present as determined by the investigator
Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) within normal range (or =< 3.0 x upper limit of normal [ULN] if liver metastases are present)
Alanine aminotransferase (ALT) and aspartate aminotransferase (AST), ?3.0 x the upper limit of normal (ULN); 5 x ULN if known hepatic metastases
Within 14 days prior to first study treatment: Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 3.0 x upper limit of normal (ULN) (unless the patient has Gilbert’s syndrome, in which case AST and ALT =< 5.0 x ULN is permitted
Aspartate aminotransferase (AST/SGOT) and alanine aminotransferase (ALT/SGPT) ? 3 x upper limit of normal (ULN) or AST or ALT ? 5 x ULN if liver is involved by disease process as judged by the investigator
Serum aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ? 2.5 upper limit of normal (ULN); if liver function abnormalities are due to the underlying malignancy, then AST and ALT must be ? 5 ULN;
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2.5 x upper limit of normal (ULN), with the following exceptions: patients with documented liver metastases: AST and/or ALT =< 5 x ULN
Patients are eligible with alanine aminotransferase (ALT) and aspartate aminotransferase (AST) measuring up to 5 x upper limit of normal (ULN) given the presence of liver metastasis
Aspartate aminotransferase (AST) =< 2.5 x upper limit of normal (ULN); if liver metastases are present, =< 5 x ULN
Aspartate aminotransferase (AST) and/or alanine aminotransferase (ALT) =< 2.5 × upper limit of normal (ULN); patient with liver metastases =< 5 ×ULN
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ? 5 × institutional upper limit of normal (ULN) for cases involving liver metastasis and ? 2.5 ×ULN for all other cases
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2.5 x upper limit of normal (ULN); except for patients with hepatic metastases: ALT and AST =< 5 x ULN
Elevated alanine aminotransferase (ALT) or aspartate aminotransferase (AST) > 2.5x the upper limit of normal, except in the presence of known liver metastases in which case levels may be up to 5x the upper limit of normal (ULN)
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 3 x upper limit of normal (ULN) (=< 5 x ULN if liver is involved by extramedullary hematopoiesis as judged by the investigator or if related to iron chelator therapy that was started within the prior 60 days)
Aspartate aminotransferase (AST) and/or alanine aminotransferase (ALT) =< 2.5 x upper limit of normal (ULN); patient with liver metastases =< 5 x ULN
Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 1.5 upper limit normal (ULN), or < 3 x ULN if liver metastases are present
Liver function tests (LFTs) (alanine aminotransferase [ALT] and aspartate aminotransferase [AST]) =< 3 X upper limit of normal (ULN)
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2.5 x upper limit of normal (ULN) with the following exception: patients with documented liver metastases should have AST and ALT =< 5 x ULN (obtained within 28 days prior to the first study treatment)
Moderate to severe liver failure (defined as alanine aminotransferase [ALT] or aspartate aminotransferase [AST] > 3 times upper limit of normal if no liver metastases are present; ALT or AST > 5 times upper limit of normal if liver metastases are present)
Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) >3 x the upper limit of normal (ULN) if no hepatic metastases are present; >5 × ULN if hepatic metastases are present
Serum aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2.5 X upper limit of normal (ULN) (or =< 5 X ULN if hepatic metastases are present)
Aspartate aminotransferase (AST) =< 2.5 x upper limit of normal range (ULN); for subjects with known liver metastases =< 5 x ULN, and alanine aminotransferase (ALT) =< 2.5 x ULN; for subjects with known liver metastases =< 5 x ULN
DONOR: History of liver disease; a donor with a history of liver disease would be eligible if the serum alanine aminotransferase (ALT) or aspartate aminotransferase (AST) are < 2 times upper limit of normal (ULN)
Alanine aminotransferase (ALT)/aspartate aminotransferase (AST) < 5 x upper limit of normal (ULN) (unless due to liver metastasis)
Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 2.5 x upper limit of normal (ULN) (=< 5 x ULN in patients with liver metastases)
Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) > 2.5 x ULN (institutional upper limits of normal); > 5 x ULN if liver metastasis
Total bilirubin ?1.5*the upper limit of the normal range (ULN), aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ?2.5*ULN (?5*ULN if liver metastases are present).
